Comparable Outcomes With and Without Neoadjuvant Therapy in High-Risk Melanoma
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Low-dose tamoxifen reduces the risk of breast cancer among patients with intraepithelial neoplasia for several years, data suggest.
Postoperative adverse events can delay chemotherapy but do not affect survival outcomes in patients with platinum-sensitive, recurrent ovarian cancer, a study suggests.
Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
Updated results support the use of adjuvant paclitaxel and trastuzumab in small, node-negative, HER2-positive breast cancer, according to researchers.
A multipronged initiative increased germline BRCA mutation testing for patients with ovarian cancer by 31%.
Compared with standard care, preoperative short-course RT followed by chemotherapy can decrease distant metastasis in patients with high-risk LARC.
Editorial board members for oncology-focused journals may sit on multiple editorial boards at the same time.
More than one-third of ASCO grants were awarded to researchers at 4 institutions.